‘There’s Only One Semaglutide’: Novo CEO Admits Compounders Are Hurting Weight Loss Business

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen on Thursday, but the company hopes to win patients over.